THALES
21.9.2020 09:02:42 CEST | Business Wire | Press release
Thales today announced the launch of the CipherTrust Data Security Platform , the industry’s first unified data protection solution that enables organisations to discover, protect, and control their most sensitive data wherever it resides. The new platform helps solve key challenges they face today. These include data security complexity caused by multi-cloud adoption, evolving global and regional privacy regulations, as well as the risk of data breaches from external and internal threats.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200921005046/en/
Drawing from years of data protection innovation, Thales has built the CipherTrust Data Security Platform to seamlessly unify data discovery, classification and data protection, along with strong access controls and centralised key management. The ‘all-in-one’ platform combines the best of Thales’s Vormetric and SafeNet KeySecure technologies to give organisations the power to keep sensitive data secure on premises or in the cloud while reducing costs and maintaining the highest levels of compliance assurance.
“CipherTrust Data Security Platform unifies the most critical elements of data security – data discovery, protection and control – into one integrated platform, providing powerful tools to address the evolving global and regional privacy regulations as well as the uptick of cloud adoption intensified by remote working,” said Todd Moore, Vice President, Encryption Solutions, Thales . “In addition to the external challenges of data protection, our new platform also helps reduce the operational complexities many organisations face, especially as businesses work to recover from the effects of the COVID-19 pandemic. This evolution of security through simplicity is exactly what organisations require now and for the future.”
Solving the Complexity Problem
Highly-distributed workforces, evolving regulations and technologies, infinite data growth and the exploding use of multi-cloud services puts sensitive data at risk, and makes data security even more challenging. According to the 2020 Thales Data Threat Report - Global Edition, organisations use 29 different cloud services on average. Lack of visibility and operational complexity has resulted in organisations not knowing where all of their sensitive data is stored. This concern around complexity (identified as the number one barrier to security by nearly 40% of the 2020 Thales Data Threat Report-Global Edition respondents) is simplified with the CipherTrust Data Security Platform.
“Complexity is one of the main barriers to deploying data security more broadly, in part because overall data security remains fairly specialised and siloed, forcing enterprises to manage multiple vendors and point products,” said Garrett Bekker, Senior Research Analyst, Information Security at 451 Research, part of S&P Global Market Intelligence, in the report, ‘Thales unites KeySecure and Vormetric product lines under CipherTrust Data Security Platform.’ “With the launch of CipherTrust Data Security Platform, Thales is looking to simplify the delivery of data security with one of the broadest data security portfolios in the market, spanning most flavours of encryption (application, database, server, file), vaulted and vaultless tokenisation, masking, key management, cloud key management, and HSMs and most recently, data discovery.”
Discover and classify sensitive data in the cloud and on-premises
As more enterprise applications and data move to the cloud and companies seek to improve scalability and deliver remote capabilities for their workforce, IT organisations will be challenged to have a holistic view of their data. As part of the platform, CipherTrust Data Discovery and Classification enables organisations to discover and classify sensitive data, as well as remediate, from a single pane of glass. Organisations can understand risks, uncover gaps, and make better decisions about both third-party data sharing and cloud migration. In addition, the solution provides a comprehensive set of built-in classification templates for commonly requested data privacy and security regulations, such as the GDPR and California Consumer Privacy Act (CCPA), but is flexible enough to handle custom policies based on specific patterns and algorithms.
Protect sensitive data anywhere with advanced encryption and tokenisation
According to IDC, more than 175 zetabytes of data will be created by 2025, and today more than half of all corporate data is stored in the cloud. To address the complexity of where data is stored, the CipherTrust Data Security Platform offers strong capabilities for securing and controlling access to sensitive data in databases, files and containers. Specific technologies include:
- CipherTrust Transparent Encryption – encrypts data across on-premises, cloud, database, file, and Big Data environments with comprehensive data access controls and detailed data access audit logging that can stop the most malicious attacks;
- CipherTrust Database Protection – provides transparent column-level encryption of structured, sensitive data residing in databases, such as credit card, social security numbers, national ID numbers, passwords and email addresses;
- CipherTrust Application Data Protection – offers APIs for developers to quickly add encryption and other crypto functions to their applications, while SecOps controls the encryption keys;
- CipherTrust Tokenisation– offers application-level data tokenisation services in two convenient solutions that deliver customer flexibility--Vaultless Tokenisation with policy-based Dynamic Data Masking and Vaulted Tokenisation; and
- CipherTrust Batch Data Transformation – provides static data masking services to remove sensitive data from production databases so compliance and security concerns are alleviated when sharing a database with third parties for analytics, testing, or other processing.
Control and centralise management of encryption keys
The accelerated adoption of encryption has led to the need to manage a far larger number of encryption keys across traditional data stores and multiple cloud environments. Proper management of encryption keys is paramount for data security because if keys are stolen, the encryption is rendered useless, and if they are lost the data is digitally shredded and cannot be recovered. This is why many organisations struggle with managing different key management solutions. CipherTrust Data Security Platform’s enterprise key management enables businesses to centrally manage and establish strong controls over encryption keys and policies for data encrypted on-premises and by cloud services. Specific technologies include:
- CipherTrust Manager– centralises keys, management and data access policies for all CipherTrust Data Security Platform products and is available in both physical and virtual form factors that are up to FIPS 140-2 Level 3 compliant;
- CipherTrust Cloud Key Manager – offers cloud bring you own key (BYOK) life cycle management for many Infrastructure, Platform- and Software as a Service cloud providers;
- CipherTrust KMIP Server – centralises key management for the standard Key Management Interoperability Protocol (KMIP) commonly used across storage solutions; and,
- CipherTrust TDE Key Manager – centralises key management for encryption found in Oracle, SQL, and Always Encrypted SQL.
Industry insight and views on the latest data security trends can be found on the Thales blog . Follow Thales on Twitter , LinkedIn , Facebook and YouTube .
About Thales Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months). Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments. |
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20200921005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
